Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy

November 09, 2000

Late-breaking presentation shows multilineage blood cell growth with excellent safety in chemotherapy patients

Maret Pharmaceuticals, Inc. today reported positive Phase I/II clinical results that demonstrate the potential of MARstem™ as a multilineage hematopoietic therapy (multiple blood cell stimulant) to treat or prevent pancytopenia (a reduction in different types of blood cells) following chemotherapy in breast cancer patients. The study was selected as a late breaking abstract at the 11th National Cancer Institute - European Organization for Research and Treatment of Cancer - American Association for Cancer Research (NCI-EORTC-AACR) Symposium on New Drugs in Cancer Therapy.

The study was designed to evaluate safety, optimal dose and proof-of-principle efficacy of MARstem in adjuvant breast cancer patients. The results show that MARstem reduced the frequency of grade 2-4 thrombocytopenia (decrease in the number of blood platelets), grade 2-4 anemia (deficiency in red blood cells), and grade 3-4 lymphopenia (reduction in the number of lymphocytes) as compared to controls.

"These early clinical results suggest that MARstem may effective in improving or reducing the debilitating side effects of cancer treatment," said Terry Winters, Ph.D., Chairman and Chief Executive Officer of Maret Pharmaceuticals. "MARstem has a clear therapeutic benefit as a multilineage hematopoietic factor as compared to traditional hematopoietic stimulants, which selectively increase only a single blood cell line. The trial's outcome is promising, as the safety of MARstem has been established and the preliminary efficacy results are encouraging."

The study's results suggest that MARstem exhibits an excellent safety profile. There were no dose-limiting toxicities in the patients treated with MARstem. Specifically, there were no adverse cardiovascular or hematologic effects. The overall occurrence of side effects was lower in MARstem patients than in control patients.

The 11th Annual NCI-EORTC-AACR symposium is being held from November 7-10 in Amsterdam. Late-breaking abstracts are selected based on highly significant subjects that present timely findings in the field of cancer therapeutics. The title of the poster presentation is "MARstem: A novel multilineage hematopoietic stimulant for chemotherapy induced pancytopenia." The poster will be presented by lead investigator, Dr. Ronald Blachly of the Northeast Arkansas Clinic on Friday, November 10.

Maret's product development focuses on MARstem, an analog of the angiotensin family of novel small peptides to treat a variety of conditions that could benefit from an increase in the formation and release of stem cells. In addition to the adjuvant breast cancer study, MARstem is currently undergoing Phase I/II clinical trials to evaluate the effects in correcting anemia in chronic renal failure patients.
-end-
Maret Pharmaceuticals is a privately held company engaged in the discovery, development, and commercialization of small peptides to assist the body to recover from injury.

Additional information and a copy of the poster presentation abstract is available on the Company's website at www.maretpharma.com.

Feinstein Kean Healthcare

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.